These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 15334472

  • 1. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
    Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I.
    Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472
    [Abstract] [Full Text] [Related]

  • 2. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
    Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R.
    Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
    [Abstract] [Full Text] [Related]

  • 3. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.
    Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ.
    Arthritis Rheum; 2003 Feb; 48(2):455-9. PubMed ID: 12571855
    [Abstract] [Full Text] [Related]

  • 4. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
    Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I.
    Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346
    [Abstract] [Full Text] [Related]

  • 5. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
    Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA.
    Arthritis Rheum; 2009 Apr 15; 61(4):482-7. PubMed ID: 19333973
    [Abstract] [Full Text] [Related]

  • 6. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG, Jones RB, Burns SM, Jayne DR.
    Arthritis Rheum; 2006 Sep 15; 54(9):2970-82. PubMed ID: 16947528
    [Abstract] [Full Text] [Related]

  • 7. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
    Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA.
    Rheumatology (Oxford); 2005 Dec 15; 44(12):1542-5. PubMed ID: 16188950
    [Abstract] [Full Text] [Related]

  • 8. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
    Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, Tanaka Y.
    Rheumatology (Oxford); 2005 Feb 15; 44(2):176-82. PubMed ID: 15494350
    [Abstract] [Full Text] [Related]

  • 9. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
    Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K.
    Arthritis Rheum; 2005 Oct 15; 52(10):3168-74. PubMed ID: 16200620
    [Abstract] [Full Text] [Related]

  • 10. An open study of B lymphocyte depletion in systemic lupus erythematosus.
    Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA.
    Arthritis Rheum; 2002 Oct 15; 46(10):2673-7. PubMed ID: 12384926
    [Abstract] [Full Text] [Related]

  • 11. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.
    Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, Nakashima H, Muta K, Abe Y, Kiyohara C, Ueda A, Nagasawa K, Yoshizawa S, Shimoda T, Harada M.
    Rheumatology (Oxford); 2008 Jun 15; 47(6):821-7. PubMed ID: 18397955
    [Abstract] [Full Text] [Related]

  • 12. Rituximab therapy for childhood-onset systemic lupus erythematosus.
    Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, Deschênes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B, French Pediatric-Onset SLE Study Group.
    J Pediatr; 2006 May 15; 148(5):623-627. PubMed ID: 16737873
    [Abstract] [Full Text] [Related]

  • 13. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy.
    Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, Sanz I.
    Arthritis Rheum; 2007 Sep 15; 56(9):3044-56. PubMed ID: 17763423
    [Abstract] [Full Text] [Related]

  • 14. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
    Kumar S, Benseler SM, Kirby-Allen M, Silverman ED.
    Pediatrics; 2009 Jan 15; 123(1):e159-63. PubMed ID: 19074962
    [Abstract] [Full Text] [Related]

  • 15. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.
    Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, Shima Y, Takada K, Matsumoto I, Saito K, Koike T.
    Mod Rheumatol; 2007 Jan 15; 17(3):191-7. PubMed ID: 17564773
    [Abstract] [Full Text] [Related]

  • 16. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.
    Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K.
    Arch Dis Child; 2008 May 15; 93(5):401-6. PubMed ID: 18039744
    [Abstract] [Full Text] [Related]

  • 17. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
    Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM.
    Arthritis Rheum; 2005 Feb 15; 52(2):501-13. PubMed ID: 15693003
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
    Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harlé JR, Hot A, Kahn JE, Lambotte O, Larroche C, Léone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE, Club Rhumatismes et Inflammation.
    Arthritis Rheum; 2010 Aug 15; 62(8):2458-66. PubMed ID: 20506527
    [Abstract] [Full Text] [Related]

  • 19. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M.
    J Rheumatol; 2008 May 15; 35(5):826-33. PubMed ID: 18398943
    [Abstract] [Full Text] [Related]

  • 20. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W.
    Ann Rheum Dis; 2008 Jul 15; 67(7):1011-6. PubMed ID: 17962238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.